ArticleScientific reports2025
Biometric analysis of disc-fovea distance and optic disc diameter in premature infants using wide-field fundus imaging.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinal biometric parameters such as disc-fovea (DF) distance and optic disc diameter (DD) are widely used to assess retinal vascularization in premature infants, evaluating the severity of retinopathy of prematurity (ROP). However, normative data for these measurements in neonates remain insufficient, and their relationship with ROP or intravitreal ranibizumab treatment is not well established. This study aimed to measure DF, DD, and DF/DD ratio in premature infants between 34 and 40 weeks of postmenstrual age (PMA), and to evaluate whether these parameters are influenced by the presence of ROP or intravitreal ranibizumab injection. A retrospective analysis was performed on wide-field fundus images from 120 premature infants, categorized into three groups: ROP infants treated with ranibizumab, ROP infants with spontaneous regression, and infants without ROP. The mean DD was 1.55 mm, showing no significant change across groups or over time. DF was 4.28-4.62 mm, displaying a decreasing trend with increasing PMA. The DF/DD ratio remained stable (3.05-3.30) across all PMA weeks and groups, with significant intergroup differences observed only at PMA 40 weeks. These findings suggest that these measurements are not significantly affected by ROP or ranibizumab treatment up to PMA 39 weeks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.